Clinical Edge Journal Scan

Migraine and Onset of Inflammatory Bowel Disease: Is There a Link?


 

Key clinical point: Patients diagnosed with migraine should be monitored for the potential onset of inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC); particularly, men with migraine may require increased monitoring for the development of UC.

Major finding: Patients with migraine had a higher risk for IBD (adjusted hazard ratio [aHR] 1.31; P < .0001), CD (aHR 1.58; P = .0002), and UC (aHR 1.26; P = .0004) than those without migraine. Presence of migraine increased the risk for UC more prominently in men (aHR 1.43; 95% CI 1.20-1.71) than in women (aHR 1.12; 95% CI 0.94-1.34; Pinteraction = .042).

Study details: The data come from a nationwide population-based cohort study that included 10,131,193 individuals who had undergone a national health examination conducted by the Korean National Health Insurance Service in 2009, of which 281,144 patients had migraine.

Disclosures: This study did not disclose the funding source. The authors declared no competing interests.

Source: Lee CH, Han K, Lee HJ et al. Migraine is associated with the development of adult patients with inflammatory bowel disease: A nationwide, population-based study. Sci Rep. 2024;14:1157 (Jan 12). doi: 10.1038/s41598-024-51455-3 Source.

Recommended Reading

Meta-analysis shows comorbid association between migraine and epilepsy
Migraine ICYMI
Patients with migraine face an elevated risk for Parkinson's disease
Migraine ICYMI
Higher delayed discounting rate among patients with episodic migraine without aura
Migraine ICYMI
Real-world comparison of treatment pattern of CGRP antibodies in migraine
Migraine ICYMI
Commentary: Gut Microbiota and CGRP in Migraine, February 2024
Migraine ICYMI
Higher vitamin B6 and folate intake tied to lower severe headache or migraine risk
Migraine ICYMI
Prednisolone May Improve MOH Withdrawal
Migraine ICYMI
No Link Between Habitual Caffeine Use and Migraine
Migraine ICYMI
Older Age at Menarche Protective Against Migraine Development
Migraine ICYMI
No Consistent Wearing-off Effects Expected for Erenumab or Fremanezumab in Chronic Migraine
Migraine ICYMI